Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB 3rd, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA; National Comprehensive Cancer Networks.

J Natl Compr Canc Netw. 2012 Jun 1;10(6):703-13.

2.

Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.

Tempero MA, Malafa MP, Behrman SW, Benson AB 3rd, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA.

J Natl Compr Canc Netw. 2014 Aug;12(8):1083-93.

PMID:
25099441
3.

Pancreatic cancer: FDG-PET is not useful in early pancreatic cancer diagnosis.

Strobel O, Büchler MW.

Nat Rev Gastroenterol Hepatol. 2013 Apr;10(4):203-5. doi: 10.1038/nrgastro.2013.42. Epub 2013 Mar 12. No abstract available.

PMID:
23478386
4.

Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology.

Tempero MA, Behrman S, Ben-Josef E, Benson AB 3rd, Cameron JL, Casper ES, Hoffman JP, Karl RC, Kim P, Koh WJ, Kuvshinoff BW 2nd, Melvin WS, Muscarella P 2nd, Sasson AR, Shibata S, Shrieve DC, Talamonti MS, Tyler DS, Vickers SM, Warren RS, Willett C, Wolff RA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 Sep;3(5):598-626. No abstract available.

PMID:
16194453
5.

Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines.

Benson AB 3rd, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fakih MG, Fleshman JW Jr, Fuchs CS, Grem JL, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett C, Freedman-Cass DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Apr;10(4):449-54.

PMID:
22491045
6.

Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.

Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA.

J Natl Compr Canc Netw. 2012 Sep;10(9):1081-7.

PMID:
22956807
8.

Ovarian cancer, version 3.2012.

Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Nov 1;10(11):1339-49.

PMID:
23138163
9.

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.

Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, Sigala F, Zorbala-Sypsa A, Felekouras E, Papalambros E.

Invest New Drugs. 2005 Aug;23(4):369-75. Erratum in: Invest New Drugs. 2005 Dec;23(6):603. Kopteridis, Petros [corrected to Kopterides, Petros].

PMID:
16012797
10.

Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines.

Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA.

J Natl Compr Canc Netw. 2013 Feb 1;11(2):141-52; quiz 152.

PMID:
23411381
11.

[Pancreatic adenocarcinoma: therapeutical update].

Khosravi Shahi P, Díaz Muñoz de la Espada VM.

An Med Interna. 2005 Aug;22(8):390-4. Review. Spanish.

PMID:
16351494
12.
13.

Interventional endoscopy, neoadjuvant therapy and the gastroenterologist.

Snady H.

Hematol Oncol Clin North Am. 2002 Feb;16(1):53-79. Review.

PMID:
12063829
14.

Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines.

Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 May 1;11(5):519-28.

PMID:
23667203
15.

Management of locally advanced adenocarcinoma of the pancreas.

Ryan DP, Willett CG.

Hematol Oncol Clin North Am. 2002 Feb;16(1):95-103. Review.

PMID:
12063831
16.

Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study.

Gunnlaugsson A, Anderson H, Lind P, Glimelius B, Johnsson A.

Radiother Oncol. 2010 Jun;95(3):292-7. doi: 10.1016/j.radonc.2010.04.004. Epub 2010 May 5.

PMID:
20451275
17.

SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma.

Rivera F, Grávalos C, García-Carbonero R; SEOM (Spanish Society of Clinical Oncology).

Clin Transl Oncol. 2012 Jul;14(7):528-35. doi: 10.1007/s12094-012-0836-9.

PMID:
22721798
18.

[Locally advanced adenocarcinoma of the pancreas: current therapeutic modalities].

Lombard-Bohas C, Mornex F, Saurin JC.

Cancer Radiother. 1997;1(5):547-54. Review. French.

PMID:
9587388
19.

5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.

Assaf E, Verlinde-Carvalho M, Delbaldo C, Grenier J, Sellam Z, Pouessel D, Bouaita L, Baumgaertner I, Sobhani I, Tayar C, Paul M, Culine S.

Oncology. 2011;80(5-6):301-6. doi: 10.1159/000329803. Epub 2011 Jul 18.

PMID:
21778770
20.

Diagnosis and management of pancreatic cancer.

Kanji ZS, Gallinger S.

CMAJ. 2013 Oct 1;185(14):1219-26. doi: 10.1503/cmaj.121368. Epub 2013 Apr 22. Review. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk